These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

510 related articles for article (PubMed ID: 22535624)

  • 1. In vitro antifungal susceptibility of filamentous fungi causing rare infections: synergy testing of amphotericin B, posaconazole and anidulafungin in pairs.
    Drogari-Apiranthitou M; Mantopoulou FD; Skiada A; Kanioura L; Grammatikou M; Vrioni G; Mitroussia-Ziouva A; Tsakris A; Petrikkos G
    J Antimicrob Chemother; 2012 Aug; 67(8):1937-40. PubMed ID: 22535624
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro activity of miltefosine as a single agent and in combination with voriconazole or posaconazole against uncommon filamentous fungal pathogens.
    Biswas C; Sorrell TC; Djordjevic JT; Zuo X; Jolliffe KA; Chen SC
    J Antimicrob Chemother; 2013 Dec; 68(12):2842-6. PubMed ID: 23861311
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.
    Pfaller MA; Messer SA; Hollis RJ; Jones RN;
    Antimicrob Agents Chemother; 2002 Apr; 46(4):1032-7. PubMed ID: 11897586
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro activities of isavuconazole against opportunistic filamentous and dimorphic fungi.
    González GM
    Med Mycol; 2009 Feb; 47(1):71-6. PubMed ID: 19101837
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antifungal susceptibilities of non-Aspergillus filamentous fungi causing invasive infection in Australia: support for current antifungal guideline recommendations.
    Halliday CL; Chen SC; Kidd SE; van Hal S; Chapman B; Heath CH; Lee A; Kennedy KJ; Daveson K; Sorrell TC; Morrissey CO; Marriott DJ; Slavin MA
    Int J Antimicrob Agents; 2016 Oct; 48(4):453-8. PubMed ID: 27562696
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Susceptibility of Mexican isolates of yeasts and moulds to amphotericin B and triazole antifungals.
    Arredondo-García JL; Amábile-Cuevas CF;
    J Infect Dev Ctries; 2009 Jun; 3(5):398-401. PubMed ID: 19759511
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
    Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
    Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Mar; 39(3):954-8. PubMed ID: 11230410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antifungal activity of a new triazole, voriconazole (UK-109,496), compared with three other antifungal agents tested against clinical isolates of filamentous fungi.
    Marco F; Pfaller MA; Messer SA; Jones RN
    Med Mycol; 1998 Dec; 36(6):433-6. PubMed ID: 10206756
    [TBL] [Abstract][Full Text] [Related]  

  • 12. New triazoles and echinocandins: mode of action, in vitro activity and mechanisms of resistance.
    Fera MT; La Camera E; De Sarro A
    Expert Rev Anti Infect Ther; 2009 Oct; 7(8):981-98. PubMed ID: 19803707
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro activity and synergism of amphotericin B, azoles and cationic antimicrobials against the emerging pathogen Trichoderma spp.
    Kratzer C; Tobudic S; Schmoll M; Graninger W; Georgopoulos A
    J Antimicrob Chemother; 2006 Nov; 58(5):1058-61. PubMed ID: 16987867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. In vitro activity of antifungal combinations against Candida albicans biofilms.
    Tobudic S; Kratzer C; Lassnigg A; Graninger W; Presterl E
    J Antimicrob Chemother; 2010 Feb; 65(2):271-4. PubMed ID: 19996142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Identification of filamentous fungi isolated from clinical samples by two different methods and their susceptibility results].
    Direkel S; Otağ F; Aslan G; Ulger M; Emekdaş G
    Mikrobiyol Bul; 2012 Jan; 46(1):65-78. PubMed ID: 22399173
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Activities of antifungal agents against yeasts and filamentous fungi: assessment according to the methodology of the European Committee on Antimicrobial Susceptibility Testing.
    Lass-Flörl C; Mayr A; Perkhofer S; Hinterberger G; Hausdorfer J; Speth C; Fille M
    Antimicrob Agents Chemother; 2008 Oct; 52(10):3637-41. PubMed ID: 18694949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antifungal susceptibility testing of Exophiala spp.: a head-to-head comparison of amphotericin B, itraconazole, posaconazole and voriconazole.
    Fothergill AW; Rinaldi MG; Sutton DA
    Med Mycol; 2009 Feb; 47(1):41-3. PubMed ID: 19107637
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the E-test with the NCCLS M38-P method for antifungal susceptibility testing of common and emerging pathogenic filamentous fungi.
    Espinel-Ingroff A
    J Clin Microbiol; 2001 Apr; 39(4):1360-7. PubMed ID: 11283057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multicenter evaluation of a new disk agar diffusion method for susceptibility testing of filamentous fungi with voriconazole, posaconazole, itraconazole, amphotericin B, and caspofungin.
    Espinel-Ingroff A; Arthington-Skaggs B; Iqbal N; Ellis D; Pfaller MA; Messer S; Rinaldi M; Fothergill A; Gibbs DL; Wang A
    J Clin Microbiol; 2007 Jun; 45(6):1811-20. PubMed ID: 17428932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of EUCAST and CLSI Reference Microdilution MICs of Eight Antifungal Compounds for Candida auris and Associated Tentative Epidemiological Cutoff Values.
    Arendrup MC; Prakash A; Meletiadis J; Sharma C; Chowdhary A
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416539
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 26.